107 related articles for article (PubMed ID: 19438741)
1. Expression of multidrug resistance-associated protein 1 in invasive ovarian carcinoma: implication for prognosis.
Faggad A; Darb-Esfahani S; Wirtz R; Sinn B; Sehouli J; Könsgen D; Lage H; Noske A; Weichert W; Buckendahl AC; Budczies J; Müller BM; Elwali NE; Dietel M; Denkert C
Histopathology; 2009 May; 54(6):657-66. PubMed ID: 19438741
[TBL] [Abstract][Full Text] [Related]
2. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
Ohishi Y; Oda Y; Uchiumi T; Kobayashi H; Hirakawa T; Miyamoto S; Kinukawa N; Nakano H; Kuwano M; Tsuneyoshi M
Clin Cancer Res; 2002 Dec; 8(12):3767-75. PubMed ID: 12473588
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.
Faggad A; Darb-Esfahani S; Wirtz R; Sinn B; Sehouli J; Könsgen D; Lage H; Weichert W; Noske A; Budczies J; Müller BM; Buckendahl AC; Röske A; Eldin Elwali N; Dietel M; Denkert C
Mod Pathol; 2009 Apr; 22(4):579-88. PubMed ID: 19270648
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
Sedláková I; Laco J; Caltová K; Červinka M; Tošner J; Řezáč A; Špaček J
Int J Gynecol Cancer; 2015 Feb; 25(2):236-43. PubMed ID: 25594141
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma.
Bagnoli M; Beretta GL; Gatti L; Pilotti S; Alberti P; Tarantino E; Barbareschi M; Canevari S; Mezzanzanica D; Perego P
Biomed Res Int; 2013; 2013():143202. PubMed ID: 24024181
[TBL] [Abstract][Full Text] [Related]
6. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic significance of Pgp, MRP1, and MRP3 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Špaček J
Ceska Gynekol; 2015 Dec; 80(6):405-13. PubMed ID: 26741154
[TBL] [Abstract][Full Text] [Related]
8. Association between multidrug resistance-associated protein 1 and poor prognosis in patients with nasopharyngeal carcinoma treated with radiotherapy and concurrent chemotherapy.
Larbcharoensub N; Leopairat J; Sirachainan E; Narkwong L; Bhongmakapat T; Rasmeepaisarn K; Janvilisri T
Hum Pathol; 2008 Jun; 39(6):837-45. PubMed ID: 18400250
[TBL] [Abstract][Full Text] [Related]
9. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
11. [Drug resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Spaček J; Cermáková E
Ceska Gynekol; 2013 Dec; 78(6):545-53. PubMed ID: 24372433
[TBL] [Abstract][Full Text] [Related]
12. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue.
Sinn BV; Darb-Esfahani S; Wirtz RM; Budczies J; Sehouli J; Chekerov R; Dietel M; Denkert C
Histopathology; 2011 Nov; 59(5):918-27. PubMed ID: 22092403
[TBL] [Abstract][Full Text] [Related]
14. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin.
Vander Borght S; Komuta M; Libbrecht L; Katoonizadeh A; Aerts R; Dymarkowski S; Verslype C; Nevens F; Roskams T
Liver Int; 2008 Dec; 28(10):1370-80. PubMed ID: 19055643
[TBL] [Abstract][Full Text] [Related]
15. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.
Hontecillas-Prieto L; Garcia-Dominguez DJ; Vaca DP; Garcia-Mejias R; Marcilla D; Ramirez-Villar GL; Saez C; de Álava E
Oncotarget; 2017 Feb; 8(7):11173-11186. PubMed ID: 28061436
[TBL] [Abstract][Full Text] [Related]
17. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
Materna V; Pleger J; Hoffmann U; Lage H
Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
19. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma.
König J; Hartel M; Nies AT; Martignoni ME; Guo J; Büchler MW; Friess H; Keppler D
Int J Cancer; 2005 Jun; 115(3):359-67. PubMed ID: 15688370
[TBL] [Abstract][Full Text] [Related]
20. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.
Obata H; Yahata T; Quan J; Sekine M; Tanaka K
Anticancer Res; 2006; 26(3B):2227-32. PubMed ID: 16821592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
